Superior COVID-19 outcomes in CML patients with controlled disease and on TKI therapies

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.